Login to Your Account

Other News To Note

Wednesday, September 18, 2013

• Alcobra Ltd., of Tel Aviv, Israel, reported preclinical results showing significant improvement in cognitive and social functioning following treatment of MG01CI (sustained-release metadoxine) in a mouse model of Fragile X syndrome.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription